Emergent BioSolutions Gains Attention as ACAM2000 Receives Expanded Authorization in Singapore

Emergent BioSolutions (EBS) announced that its vaccine ACAM2000 received expanded authorization from Singapore's Health Sciences Authority for use against mpox. This approval broadens the vaccine’s application and highlights EBS' role in public health preparedness. Additionally, Emergent entered a $50 million collaboration with SAB Biotherapeutics to develop an autoimmune type 1 diabetes candidate.

By Laiba Immad Wed, May 20, 2026 at 11:43 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 20:43 UTC

Tickers: $EBS

Topics: medical countermeasures pharmaceuticals public health

Read the full article at Yahoo Finance

More World news

Avicanna Reports Q3 Results with Positive Adjusted EBITDA and Reduced Operating Losses Seeking Alpha · November 12, 2026, 14:29 UTC
Bridgemarq Real Estate Services Announces Monthly Dividend of CAD 0.0125 per Share Seeking Alpha · November 12, 2026, 14:29 UTC
Natus Medical Expands Global Clinical Collaboration via New EMG and EEG Advisory Boards PR Newswire · November 12, 2026, 14:33 UTC
CoreWeave Reports Strong Third-Quarter Results Driven by AI Demand Motley Fool · November 12, 2026, 14:30 UTC
Baker Hughes and TPAO Partner to Develop Enhanced Geothermal Systems in Turkey Seeking Alpha · November 12, 2026, 14:25 UTC
Twist Bioscience Shares Fall Following Weak Fiscal 2027 Guidance Despite Q4 Revenue Beat Seeking Alpha · November 12, 2026, 14:26 UTC
Metatek-Group Ltd. Reports Q3 Revenue Growth of 29.3% to $9.7 Million Seeking Alpha · November 12, 2026, 14:26 UTC
Spout Finance Integrates Ondo Stocks to Enable Interest-Free USDC Borrowing via Covered Calls PR Newswire · November 12, 2026, 14:30 UTC
Deswell Industries Announces Semi-Annual Dividend of $0.10 Per Share Seeking Alpha · November 12, 2026, 14:24 UTC
Nvidia Shares Plunge Following Announcement of CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 14:24 UTC